BOW030 (bevacizumab biosimilar) / Epirus - LARVOL DELTA

Novel Drug Delivery System for the Management of Wet AMD - Episode 3: Treat and Extend Approach to Anti-VEGF Therapy for AMD (HCPLive) - "Diana Do, MD: I agree, Carl. Clearly, intravitreal VEGF inhibitors, which are administered in the clinic, are the first-line treatment for wet age-related macular degeneration. There are 4 medicines available in clinical use. Three of these agents are FDA approved: ranibizumab, aflibercept, and brolucizumab. One agent, bevacizumab, is used off-label. Fortunately, there's a robust body of scientific evidence that suggests all these medicines are very efficacious when dosed appropriately for the treatment of wet macular degeneration."

Video